Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.01.038 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.01.038 33484862!7817432!33484862     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 263.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 104 (ä): 661-669 Nephropedia Template TP {{tp|p=33484862|t=2021. Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients |pdf=|usr=}}{{33484862}} gab.com Text Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33484862 #FOAvip BACKGROUND: Commercial availability of serological tests to evaluate immunoglobulins (Ig) targeting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has grown exponentially since the start of the coronavirus disease 2019 (COVID-19) outbreak. Thorough validation of these tests is important before use as epidemiological tools to infer seroprevalence in specific populations and as diagnostic tools to complement molecular approaches (e.g., quantitative reverse transcription-polymerase chain reaction). METHODS: Commercial serological tests from 11 suppliers were assayed side-by-side using 126 samples from SARS-CoV-2-infected inpatients and 36 from healthy and HIV-infected individuals. RESULTS: The majority of the tests assayed have >95% specificity. For the sensitivity calculation, samples were stratified by days since symptoms onset; sensitivity peaks at 16-21 days for IgM and IgA (maximum 91.2%, Euroimmun) and, dependant on the test, at 16-21 or >21 days for IgG (maximum 94.1%, Snibe). Data from semiquantitative tests show that patients with a severe clinical presentation have lower levels of Ig targeting SARS-CoV-2 at <10 days since symptoms onset and higher levels at >21 days, compared to patients with a non-severe presentation. CONCLUSIONS: This study highlights the heterogeneity of sensitivity and generally high specificity of the serological tests and establishes a basis for their usefulness to complement diagnostic techniques and population seroprevalence studies. Twit Text FOAVip Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33484862 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33484862 #FOAvip English Wikipedia <ref>{{Cite pmid|33484862}}</ref> Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients #MMPMID33484862 Serre-Miranda C; Nobrega C; Roque S; Canto-Gomes J; Silva CS; Vieira N; Barreira-Silva P; Alves-Peixoto P; Cotter J; Reis A; Formigo M; Sarmento H; Pires O; Carvalho A; Petrovykh DY; Dieguez L; Sousa JC; Sousa N; Capela C; Palha JA; Cunha PG; Correia-Neves M Int J Infect Dis 2021[Mar]; 104 (ä): 661-669 PMID33484862show ga BACKGROUND: Commercial availability of serological tests to evaluate immunoglobulins (Ig) targeting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has grown exponentially since the start of the coronavirus disease 2019 (COVID-19) outbreak. Thorough validation of these tests is important before use as epidemiological tools to infer seroprevalence in specific populations and as diagnostic tools to complement molecular approaches (e.g., quantitative reverse transcription-polymerase chain reaction). METHODS: Commercial serological tests from 11 suppliers were assayed side-by-side using 126 samples from SARS-CoV-2-infected inpatients and 36 from healthy and HIV-infected individuals. RESULTS: The majority of the tests assayed have >95% specificity. For the sensitivity calculation, samples were stratified by days since symptoms onset; sensitivity peaks at 16-21 days for IgM and IgA (maximum 91.2%, Euroimmun) and, dependant on the test, at 16-21 or >21 days for IgG (maximum 94.1%, Snibe). Data from semiquantitative tests show that patients with a severe clinical presentation have lower levels of Ig targeting SARS-CoV-2 at <10 days since symptoms onset and higher levels at >21 days, compared to patients with a non-severe presentation. CONCLUSIONS: This study highlights the heterogeneity of sensitivity and generally high specificity of the serological tests and establishes a basis for their usefulness to complement diagnostic techniques and population seroprevalence studies. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/*diagnosis[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology[MESH] |Sensitivity and Specificity[MESH]Performance assessment of 11 commercial serological tests for SARS-CoV(epmc).pdf DeepDyve Pubget Overpricing